Emerg Infect Dis by Colavita, Francesca et al.
lineages are widespread and common in northern Eng-
land. Furthermore, the considerable sequence diver-
gence between samples in Cheshire and Northumberland 
is consistent with a long-standing endemicity in northern 
England. Given that PUUV has never been recorded in 
the United Kingdom (2,10), the possibility should be 
considered that a Tatenale-like virus could have been 
responsible for some of the HFRS cases that have oc-
curred here. More studies are needed to confirm whether 
other common rodents in the United Kingdom are hosts 
for this virus and to further characterize its phyletic re-
lationships and zoonotic potential. Cross-reactivity of 
the sera from Tatenale-like virus–infected individuals to 
antigens of other relevant hantaviruses should be deter-
mined to inform future serologic surveys and the diagno-
sis of human HFRS cases.
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The recent Ebola outbreak in West Africa caused breakdowns 
in public health systems, which might have caused outbreaks 
of vaccine-preventable diseases. We tested 80 patients admit-
ted to an Ebola treatment center in Freetown, Sierra Leone, 
for measles. These patients were negative for Ebola virus. 
Measles virus IgM was detected in 13 (16%) of the patients.
The Ebola virus disease (EVD) outbreak in West Africa during 2013–2016 was one of the worst public health di-
sasters in recent history; it caused >28,646 cases and 11,323 
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deaths (1). Consequences of EVD include social instability, 
poor food reserves, breakdown of healthcare systems, and 
reduced vaccination coverage (2,3). Breakdown of health-
care systems and reduced vaccination coverage might have 
been the worst consequences because nearly all health re-
sources were shifted to the EVD response. Disruptions of 
local health systems could lead to underreporting of other 
infectious diseases cases and a second crisis that could kill as 
many as persons as the original outbreak, if not more.
The 3 countries most affected by this outbreak (Sierra 
Leone, Guinea, and Liberia) have been a major part of the 
World Health Organization Expanded Programme on Im-
munization through vaccination campaigns for reducing 
childhood deaths from vaccine-preventable diseases, such as 
measles. Although there are no cures for EVD or measles, 
a potent measles vaccine is available, which can prevent 
spread of this disease. Use of this vaccine is crucial because 
measles is far more contagious (1 case-patient with measles 
can transmit infection to 12–18 persons) than EVD and 
might be the primary cause of major epidemics (3,4). These 
3 countries reported nearly 93,685 cases of measles during 
1994–2003 (although Sierra Leone did not report cases for 4 
years), and during November 1, 2009–July 13, 2010, a total 
of 1,094 confirmed measles cases were reported in Sierra Le-
one. Plans for measles vaccination campaigns were imple-
mented before the EVD outbreak because of an increase in 
susceptibility to measles in these 3 countries (3,5).
Historically, measles outbreaks have followed hu-
manitarian crises, such as war (6), natural disasters (7), and 
political crises (8). Recent studies have shown that measles 
is one of the causative agents of secondary outbreaks dur-
ing the EVD epidemics in West Africa (9), probably due 
to the disruption in vaccination campaigns, nonfunctional 
healthcare systems (including detection and reporting of 
measles cases), lack of specific treatment, and a sense of 
fear of contracting EVD with reluctance to approach health 
assistance (10).
Probable underreporting of and lack of data for mea-
sles cases during EVD outbreaks prompted us to investigate 
measles in Sierra Leone during the recent EVD outbreak. 
Although during the preparedness phase of the European 
Mobile Laboratory Project (http://www.emlab.eu), measles 
was to be included among diseases tested for differential 
diagnosis of EVD, we could not implement this approach 
in the field during the outbreak.
We performed a retrospective serologic study to par-
tially investigate the role of measles in the EVD outbreak 
by testing serum samples negative for Ebola virus by re-
verse transcription PCR for measles virus IgM from per-
sons suspected of having EVD. Samples were obtained 
at the Emergency Nongovernmental Organization Ebola 
Treatment Center (Goderich, Freetown, Sierra Leone). This 
study was approved by Ethical Committee of Sierra Leone.
We analyzed 80 patients, of whom 27 were >8 years 
of age and <25 years of age (median age 30 years) during 
December 2014–June 2015, who had fever (temperature 
>37.5°C) and diarrhea or vomiting. Only 1 patient had a his-
tory of rash. Measles virus IgM was detected by using an in-
direct immunofluorescence assay for 13 patients (16%), most 
(69%) of whom were in this age group (p<0.001). Although 
we could not determine whether measles IgM in these pa-
tients was caused by vaccination failures during the outbreak 
or failures of the Expanded Programme on Immunization, 
this age distribution might be indicative of noneffective im-
munization campaigns, especially a deficiency in the health-
care system in detecting and reporting measles cases.
The recent EVD outbreak caused breakdowns of 
healthcare systems in the affected countries, leading to pos-
sible secondary outbreaks (2,3). A higher risk for vaccine-
preventable diseases, in particular measles, is often an early 
result in interruption in delivery of public health services. 
Recent studies have shown that the increase in measles cas-
es during the EVD outbreak in 2013–2016 was caused by 
disruption of vaccination programs and underreporting of 
measles cases, which is probably related to effects of EVD 
on healthcare systems (9).
Our results for samples obtained from Ebola-negative 
patients showed a high number of measles infections dur-
ing the outbreak in different age groups. Although few (n 
= 80) patients have been tested, our results provide useful 
insights into measles cases during other outbreaks in dif-
ferent age groups, adding new evidence from a study that 
focused on children (9).
Our findings indicate the need for correct and rapid dif-
ferential diagnoses during such outbreaks to avoid spread 
of other infectious diseases. Furthermore, local public 
health systems should be strengthened in those countries 
that are now recovering from the EVD outbreak to reduce 
risks for other infectious diseases outbreaks.
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Infection with Angiostrongylus cantonensis roundworms is en-
demic in Southeast Asia and the Pacific Basin. A. cantonensis 
meningitis and myelitis occurred in summer 2013 in a child with 
no history of travel outside of Texas, USA. Angiostrongyliasis 
is an emerging neurotropic helminthic disease in Texas and 
warrants increased awareness among healthcare providers.
In summer 2013, a previously healthy Caucasian 12-month-old girl was brought for treatment to a chil-
dren’s hospital in Houston, Texas, USA, on the 11th day 
of illness (day 11), manifesting intermittent fever, lethargy, 
and emesis. She had been evaluated by a pediatrician on 
day 3 and diagnosed with presumed viral infection. She at-
tended day care, had no history of sick contacts, and apart 
from dogs in the house, had no notable other exposures. 
At hospital admission, physical examination showed 
vital signs within reference ranges, mild distress, lethargy, 
and irritability with no focal deficits or signs of meningeal 
irritation. Blood test results showed leukocytosis (17,900 
cells/mm3 with 20% eosinophils). Cerebrospinal fluid 
(CSF) examination showed 8 erythrocytes and 568 leuko-
cytes/mm3 with 26% eosinophils. Results of bacterial cul-
tures and PCR of CSF for herpes simplex virus and entero-
virus were negative. She had no serologic evidence of acute 
infection with West Nile virus or HIV. Magnetic resonance 
imaging (MRI) of the brain showed normal results. She re-
ceived ceftriaxone, vancomycin, and acyclovir from days 
11 through 15 with no clinical improvement. 
On day 16, because the child had been exposed to dogs, 
she was empirically treated for presumed Toxocara infec-
tion with albendazole and prednisone for 5 days. Her clinical 
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